Table 1.

Patient characteristics

		All (n = 62)	DR (n = 11)		True PD (n = 51)		P
		n	n	%	n	%
Age	median 65, range 27–82
	≥75	11	2	18	9	18	1.000
	< 75	51
Gender	Male	40	7	64	33	65	1.000
	Female	22
Performance status	0,1	46	8	73	38	75	1.000
	2–4	16
Smoking status	Current/former	45	6	55	39	76	0.155
	Never	17
Histology	Squamous cell carcinoma	12	2	18	10	20	1.000
	Non-squamous cell carcinoma	50
	Adenocarcinoma (n = 46), Others (n = 4)
Driver mutation	Positive	15	3	27	12	24	0.696
	EGFR L858R/19del (n = 12), ALK (n = 3)
	Negative	47
Line of treatment	2nd line	32	7	64	25	49	0.511
	3rd line or beyond	30
PD-L1 status	<  1	8	0	0	8	16
	1 ≤	28	7	64	21	41
	Unknown	26	4	40	22	43
Treatment	Nivolumab	45	9	20	36	80
	Pembrolizumab	7	2	29	5	71
	Atezolizumab	10	0	0	10	100

Abbreviations: DR dissociated responses, PD-L1 programmed cell death-ligand 1, True PD true progressive disease